Haloperidol versus placebo for schizophrenia.

Area of Science:

• Psychiatry and Pharmacology
• Clinical Trial Analysis

Background:

• Haloperidol, initially developed for anesthesia, emerged as an antipsychotic due to its efficacy in managing psychosis.
• Its effects on hallucinations, delusions, and aggressive behavior led to its widespread clinical adoption.

Purpose of the Study:

• To systematically evaluate the clinical effectiveness of haloperidol versus placebo in treating schizophrenia.
• To assess haloperidol's impact on clinical and social response, relapse rates, and adverse effects.

Main Methods:

• Conducted a comprehensive literature search of multiple databases (e.g., MEDLINE, EMBASE, PsycLIT) from inception to 1998, with an update in 2005.
• Included randomized controlled trials (RCTs) comparing oral haloperidol with placebo in patients with schizophrenia or similar psychoses.
• Analyzed data using intention-to-treat principles, calculating relative risks (RR) and number needed to treat/harm (NNT/NNH).

Main Results:

• Twenty-one RCTs involving 1519 participants were included.
• Haloperidol demonstrated significant improvement in symptoms within the first six weeks (NNT=3) and over 6-24 weeks.
• However, haloperidol significantly increased the risk of acute dystonia (NNH=5), akathisia (NNH=7), and parkinsonism (NNH=3).

Conclusions:

• Haloperidol is an effective antipsychotic but is associated with a high incidence of movement disorders.
• Its use may be justified when no other treatment options exist for severe schizophrenia.
• Alternative antipsychotics with a lower risk of adverse effects are preferable when available.